Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines ...

Timely transplant referral depends on disease kinetics. Novel therapies are among the unmet needs in plasmacytoid dendritic cell neoplasm. Support resources aid patient management. Emerging treatments ...

At stage 0, atypical cells are only present in the top layer of the skin or tissue. It has not become cancer yet and has not spread anywhere else. Doctors sometimes call this stage “carcinoma in ...

An expert discusses how, for younger/fitter patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), treatment selection as a bridge to transplant is based on efficacy, toxicity, and ...

A promising lead has emerged from examining the interaction between the tumor and immune cells, including CAR T cells. The findings are published in the Blood Journal. It turns out that B-ALL ...

These take instructions from the white blood cells known as dendritic cells, which he refers to as the "generals" of the immune system. When these generals sense danger they become excited and ...

About ELZONRIS® (Tagraxofusp-erzs) U.S. Indication: ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and ...

About BPDCN BPDCN, formerly blastic NK-cell lymphoma ... lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the ...